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ABSTRACT 
A novel treatment for cancer patients with homozygous deletions of BRCA1 and BRCA2 is to use drugs that inhibit the 
enzyme poly(ADP-ribose) polymerase (PARP). Specific inhibition of PARP-1 can induce synthetic lethality in irradi- 
ated cancer cells while theoretically leaving normal tissue unaffected. We recently demonstrated in a cell survival assay 
that lymphoblastoid cells with mono-allelic mutations of BRCA1 were hypersensitive to gamma radiation in the pres- 
ence of the PARP-1 inhibitor Olaparib compared to normal cells and mono-allelic BRCA2 cells. To determine if the 
enhanced radiation sensitivity was due to a persistence of DNA strand breaks, we performed γ-H2AX foci analysis in 
cells derived from two normal individuals, three heterozygous BRCA1 and three heterozygous BRCA2 cell lines. Cells 
were exposed to 2 Gy gamma radiation in the presence or absence of 5 µM Olaparib. Using immunofluorescence and 
imaging flow cytometry, foci were measured in untreated cells and at 0.5, 3, 5 and 24 hours post-irradiation. In all 
lymphoblastoid cells treated with 2 Gy gamma radiation, there was a predictable induction of DNA strand breaks, with 
a modest but significant retention of foci over 24 hours in irradiated cells treated with Olaparib (ANOVA P < 0.05). 
However, in mono-allelic BRCA1 cells, there was a failure to fully repair DNA double-strand breaks (DSB) in the pres- 
ence of Olaparib, evidenced by a significant retention of foci at 24 hours’ post irradiation (t-Test P < 0.05). These data 
show that the cellular hypersensitivity of mono-allelic BRCA1 lymphoblastoid cells to gamma radiation in the presence 
of the Olaparib is due to the retention of DNA DSB. These data may indicate that patients with inherited mutations in 
the BRCA1 gene treated with radiotherapy and PARP-1 inhibitors may experience elevated radiation-associated normal 
tissue toxicity. 
 
Keywords: BRCA1; BRCA2; Heterozygote; Radiosensitivity; PARP Inhibitor; Gamma-H2AX; Imaging Flow  
Cytometry 
1. Introduction 
BRCA1 (BReast-CAncer susceptibility gene 1) and BRCA2 
are tumour suppressor genes, the protein products of 
which contribute to DNA repair and transcriptional regu- 
lation. The BRCA proteins are activated in response to 
DNA damage such as double-strand breaks (DSB), form- 
ed by exposure to ionising radiation [1]. DSB repair is me- 
diated by two principal mechanisms: non-homologous end 
joining (NHEJ) and homologous recombination (HR). 
NHEJ occurs principally in non-cycling and G1 stage  
cells, where the DNA DSB are ligated together in an er- 
ror-prone manner. Here the BRCA1 protein is associated 
with the MRN complex, which senses DSB and is re- 
sponsible for DSB resolution. HR repairs DSB during the 
S and G2 phases of the cell cycle, when an intact sister 
chromatid can serve as a template for repair, a mecha- 
nism that is virtually error-free. Both BRCA1 and BRCA2 
proteins are active in HR. BRCA1 is a signal mediator, 
whereas BRCA2 affects the initiation of repair by recruit- 
ing Rad51 to DSB. Hence BRCA1 is a versatile protein 
with multiple functional domains that interacts with many  
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other proteins in both the NHEJ and HR pathways. 
BRCA2, however, is restricted to HR [2]. Both proteins 
are crucial components in the repair of ionising radiation- 
induced DSB. 
A mutation in either of the BRCA genes predisposes 
individuals to a number of cancers, especially breast can- 
cer. Somatic mutations are responsible for the majority of 
cases, however germline mutations in these genes are ob- 
served in approximately 5% - 10% of breast cancers [3]; 
such cases are also characterised by early onset [4]. In 
addition, mutations of these genes are implicated in can- 
cers of the ovary, prostate, pancreas and male breast [3]. 
Such cancers are routinely treated with a regime of radi- 
otherapy, chemotherapy or surgery, or a combination of 
these methods, which have proved over many decades to 
be highly effective in extending patient survival and era- 
dicating certain types of tumours [5]. Radiotherapy is us- 
ually administered in fractionated doses, which enables 
the patient to better tolerate treatment by giving normal 
tissue time to recover in between fractions [6]. However, 
patients receiving identical radiotherapy treatments may 
experience widely-differing level of normal tissue toxic- 
ity (NTT), ranging from undetectable to unacceptably se- 
vere [7]. Such side-effects have been classified according 
to tissue type and symptoms exhibited; classification sys- 
tems include that produced by The Radiation Therapy 
Oncology Group/European Organization for Research and 
Treatment of Cancer (RTOG/EORTC), and the Late Ef- 
fects Normal Tissue Task Force subjective, objective, ma- 
nagement, and analytic (LENT/SOMA) [8]. Although the 
majority of NTT reactions can be predicted with reason- 
able accuracy, a small minority of patients experience se- 
vere responses to radiotherapy that fall outside the pub- 
lished NTT classifications and such individuals are re- 
ferred to as “over-reactors”. Mainly these individuals har- 
bour inherited genetic defects in the repair of DNA DSB, 
including those affecting the ATM gene (Ataxia Telangi- 
ectasia) [9], the DNA-PKcs gene [10], and the Artemis 
gene, which results in Radiosensitive Severe Combined 
Immunodeficiency Disorder (RS-SCID) [11]. These cases 
exhibit clinical and cellular radiosensitivity so extreme as 
to be potentially fatal to the patient. 
The crucial role of the BRCA1 and BRCA2 proteins in 
DNA DSB repair suggests that individuals carrying mu- 
tations in these genes may be susceptible to elevated ra- 
diotherapy-induced NTT, however published data is far 
from clear on this issue. For example, an in vitro study of 
lymphocytes and fibroblasts derived from patients het- 
erozygous for either BRCA1 or BRCA2 found that the fi- 
broblasts were radiation hypersensitive in a clonogenic 
assay and the lymphocytes displayed elevated chromoso- 
mal aberrations after radiation exposure [12]. These ob-  
servations suggest that such individuals may experience 
increased NTT during radiotherapy. However, other stu- 
dies have demonstrated that in those patients who do suf- 
fer elevated NTT, BRCA1 and BRCA2 heterozygosity is 
rarely or not observed [13]. This suggests that genes other 
than BRCA1 and BRCA2 probably account for most cases 
of clinical radiation hypersensitivity leading to NTT. 
Additional to DSB, ionising radiation will also induce 
DNA single-strand breaks (SSB). Such damage will ini- 
tiate the short-patch and long-patch base-excision repair 
(BER) pathways. Short-patch BER involves the removal 
of an incorrect or damaged base; members of the poly 
(ADP-ribose) polymerase (PARP) enzyme family are re- 
cruited to the damage site to replace the base and religate 
the DNA [14]. Nicotinamide, a catalytic by-product of 
these reactions, was identified as a weak PARP inhibitor, 
revealing a platform to develop synthetic PARP inhibi- 
tors, such as the benzamides [15]. These were superseded 
by more specific and potent compounds, including AZD- 
2281 (Olaparib). Studies on cells derived from head and 
neck tumours, and from lymphomas, showed that Olapa- 
rib produced a synergistic effect when used in concert 
with ionising radiation [16]. 
Our lab previously examined the response to ionising 
radiation of lymphoblastoid cells mono-allelic for either 
BRCA1 or BRCA2 mutations [17]. In this work, two lym- 
phoblastoid cell lines derived from normal individuals 
and three from individuals with heterozygous mutations 
in the BRCA1 or BRCA2 genes were used. The cells were 
exposed to increasing doses of gamma radiation either 
alone or in concert with 5 µM Olaparib, with the MTT 
assay used to measure cell survival. As expected, expo- 
sure to increasing doses of gamma radiation caused an 
increase in cell death of all cell types. Simultaneous ex- 
posure to gamma radiation and 5 µM Olaparib did not 
enhance cell death in normal or BRCA2 heterozygote 
cells, but significantly enhanced cell death in the mono- 
allelic mutated BRCA1 cells. In the light of this finding, 
we cautioned that the treating cancer patients carrying 
BRCA1 gene mutations with radiotherapy combined with 
Olaparib administration may enhance radiation-induced 
normal tissue toxicity (NTT). 
The MTT assay is an established method to determine 
cell survival. However, we were interested in confirming 
our hypothesis that cell death was caused by the persis- 
tence of DNA single- and double-strand breaks due to the 
combined radiation exposure and PARP-1 inhibition by 
Olaparib. Theoretically, the number of DSB in the lym- 
phoblastoid cells mono-allelic for BRCA1 mutations would 
be greater in comparison to those in the normal cell lines 
and those mono-allelic for BRCA2 mutations. 
The phosphorylation of the histone protein H2AX is 
an important event in the signalling and subsequent re- 
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pair of DNA DSB. The protein product of this reaction 
(γ-H2AX) accumulates at the sites of DSB, forming nu- 
clear foci where the number of foci is indicative of DNA 
DSB. These foci can be visualised with immunocyto-che- 
mistry methods [18,19]. 
In cells normal for DNA DSB repair, these foci appear 
rapidly post-irradiation, then disappear within 1 - 3 hours, 
as the associated DSB are repaired and the γ-H2AX mo- 
lecules become de-phosphorylated. In cells with defec- 
tive DSB repair, the persistence of DNA strand breaks 
correlates with the persistence of γ-H2AX foci. Hence it 
is possible to visualise and quantitate in a time-dependent 
manner the repair of DSB in many cell lines. 
In this study we demonstrate that the levels of cell 
death in normal, BRCA1-mutated and BRCA2-mutated 
cells exposed to the PARP inhibitor Olaparib and gamma 
radiation as observed in our previous work [17] corre- 
lated with the frequency and persistence of γ-H2AX foci 
in these same cells. 
2. Materials and Methods 
2.1. Cell Lines 
Human B lymphocytes which had been immortalised 
using the Epstein-Barr virus were purchased from Coriell 
Cell Repositories (Camden, New Jersey, USA). Details 
of the cell lines are shown in Table 1. Cell lines 
“BRCA1” and “BRCA2” were heterozygotes for muta- 
tions in the BRCA1 or BRCA2 genes, respectively. 
Table 1 provides a description of the B-lymphoblas- 
toid cell lines used in the study together with the infor- 
mation on the mono-allelic mutation in the BRCA1 and 
BRCA2 heterozygous cell lines. 
2.2. Cell Culture 
The cell lines were routinely cultured in T75 cell culture 
flasks (PAA Laboratories Limited, Yeovil, Somerset, UK) 
in RPMI 1640 culture medium (Sigma-Aldrich, Poole, 
Dorset, UK) supplemented with 10% foetal bovine serum,  
2.0 mM L-Glutamine and 100 Uml−1 Penicillin and 
Streptomycin (PAA). Cells were incubated at 37˚C in a 
humidified atmosphere of 5% CO2 in air. 
Cell concentration and viability values were determin- 
ed using a “Countess™” automated cell counter based 
upon the method of trypan blue exclusion (Invitrogen, 
Paisley, Renfrewshire, UK). Cell cultures were used over 
a restricted range of ten passages, during which cell via- 
bility was not less than 80%. 
2.3. Exposure to the PARP Inhibitor Olaparib 
The highest non-cytotoxic concentration of Olaparib (LC 
Laboratories Inc, Woburn, Massachusetts, USA) was de- 
termined previously [17]. However, in brief, cells were 
exposed to increasing concentrations of the drug in the 
range of 1.0 µM to 1000.0 µM (log10 scale). The cells 
were incubated in the drug for 3, 5 and 7 days and sur- 
vival was determined using the MTT assay. The appro- 
priate concentration of Olaparib was found to be 5.0 µM 
following a 7 day exposure; this was the maximum con- 
centration of Olaparib that did not cause significant cell 
death. 
2.4. Exposure to Radiation 
The cell suspension of each cell line was divided in half 
and the cells concentrated into pellets by centrifugation 
at 1500 rpm for 5 minutes using a table top centrifuge. 
Each cell pellet was re-suspended with either complete 
medium only or a 5.0 µM solution of PARP inhibitor in 
complete medium to create two separate cell suspensions, 
which were incubated for 1 hour (incubation conditions 
detailed previously). One 5.0 ml aliquot from each cell 
suspension was designated as an un-irradiated control; 
the remaining suspensions were irradiated with 2 Gy 
gamma radiation from a 60Cobalt source (Puridec Tech- 
nologies, Oxfordshire, UK) sited at a distance of 25 cm 
with a dose rate of 0.9 Gy per minute. 
The cell suspensions were returned to the incubator  
 
Table 1. Description of B-lymphoblastoid cell lines used in study. 
Cell Line Type Details of BRCA Gene Mutation 
GM00893 Normal None 
GM05423 Normal None 
GM13705 BRCA1 4-base pair deletion in exon 11 = truncated protein.  
GM14090 BRCA1 2-base pair deletion in exon 3 = truncated protein. 
GM16105 BRCA1 Base substitution in intron 8. 
GM14170 BRCA2 1-base pair deletion in exon 11 = frameshift mutation. 
GM14622 BRCA2 2-base pair deletion in exon 11 = frameshift mutation = truncated protein. 
GM14805 BRCA2 Base substitution in exon 7 = nonsense mutation.  
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(incubation conditions detailed previously), and 5.0 ml 
aliquots removed at 30 minutes, 3 hours, 5 hours and 24 
hours after irradiation. Cells in each aliquot were washed 
once with ice-cold PBS (Severn Biotech Ltd, Kiddermin- 
ster, Worcestershire, UK) and fixed in ice-cold metha- 
nol:acetone (50:50 v/v). Two compensation samples for 
imaging flow cytometry were prepared in the same way 
at the 30 minute time-point. Samples were stored at 
−20˚C until the immunocytochemistry stage. The immu- 
nocytochemistry stage commenced within 5 days of the 
24 hour time-point sample being fixed. 
2.5. Immunocytochemistry 
Cells were washed once in ice-cold PBS (Severn Biotech 
Ltd) then incubated with gentle agitation for 5 minutes at 
room temperature in permeabilisation buffer consisting 
of 0.5% Triton™ X-100 (Sigma-Aldrich) in PBS. Cells 
were then incubated with gentle agitation for 1 hour at 
room temperature in blocking buffer consisting of 5.0% 
rabbit serum (PAA) with 0.1% Triton™ X-100 in PBS. 
The blocking buffer was removed and the cells incubated 
with gentle agitation overnight at 4˚C in primary anti- 
body solution. The primary antibody solution consisted 
of an anti-phospho-histone H2AX (serine 139), mouse 
monoclonal IgG1 antibody, clone JBW301 (Millipore, 
Watford, Hertfordshire, UK) diluted 1 in 10,000 in blo- 
cking buffer. Excess primary antibody was removed by 
washing twice with wash buffer, consisting of 0.1% Tri- 
ton™ X-100 in PBS. The secondary antibody solution 
consisted of an Alexa Fluor®488 rabbit anti-mouse IgG 
antibody (Invitrogen) diluted 1 in 1000 in blocking buf- 
fer. This was added to each sample, except the DRAQ5™ 
compensation samples, and incubated with gentle agita- 
tion for 1 hour at room temperature. Excess secondary 
antibody was removed by washing twice with wash buf- 
fer. The cells were re-suspended in 100 µl Accumax™ 
solution (PAA) and left overnight at 4˚C (no agitation). 
1.0 µl of 5 mM DRAQ5™ solution (Cell Signaling Te- 
chnology, Hitchin, Hertfordshire, UK) was added to each 
sample, except the AlexaFluor®488 compensation sam- 
ples. The samples were submitted for analysis by imag- 
ing flow cytometry. 
2.6. Imaging Flow Cytometry 
Imaging flow cytometry was conducted using the Im- 
agestreamX system (Amnis Inc., Seattle, Washington, 
USA). This permits image capture of each cell in flow 
using a maximum of six optical channels. Using the In- 
spire™ data acquisition software, images of 10,000 cells 
were captured on channel 1 for brightfield (BF); on chan- 
nel 2 for Alexa Fluor®488 (AF), representing the green 
staining of γ-H2AX foci; and on channel 5 for the blue 
DRAQ5™ (D5) staining of the nuclear region of each 
cell. Cell classifiers were applied to the BF channel to 
capture objects that ranged between 50 and 300 units on 
an arbitrary scale. These values were determined from 
previous analyses whereby this classifier range was ob- 
served to capture primarily single cell images. Following 
excitation with a 488 nm laser at a power setting of 40 
mW, all images were captured using a 40× objective. 
Images of cells were acquired at a rate of 150 - 200 cell 
images per second. 
2.7. Image Compensation 
Image compensation was performed on populations of 
cells that had been fixed 30 minutes post-irradiation in 
which -H2AX staining intensity was likely to be highest. 
Cells that were stained with antibody only or DRAQ5™ 
only were used for generating the compensation matrix. 
These images were collected without brightfield or dark- 
field illumination since it was important to capture fluo- 
rescence intensity with the 488 nm laser as the single 
source of illumination. The Ideas™ software compensa- 
tion wizard generates a table of coefficients whereby 
detected light that is displayed by each image is placed 
into the proper channel (channel 2 for antibody staining 
and channel 5 for DRAQ5™) on a pixel-by-pixel basis. 
The coefficients were normalized to 1 and each coeffi- 
cient represents the leakage of fluorescent signal into 
juxtaposed channels. Calculated compensation values were 
applied to all subsequent analyses as appropriate. 
2.8. Analysis of Cell Images and Calculation of 
Foci Number 
γ-H2AX foci were quantified in approximately 10,000 
images of cells captured using the Inspire™ imaging 
flow cytometry software. Foci were quantified in a simi- 
lar manner as previously described [19], however, the 
spot counting wizard provided in Ideas™ was used to 
simplify foci quantitation. In brief, a series of simple 
building blocks are used to first identify and gate single 
cells, then a region is drawn to identify those single cells 
that are in the correct focal plane during imaging flow. 
Next, two truth populations were identified by the op- 
erator which includes images of cells that have few foci 
(less than 5) which equates to the first truth population. 
Finally a second truth population is created which identi- 
fies cells with a large number of foci (greater than 8 - 10). 
These truth populations are then saved and used by the 
Ideas™ software to create a feature which enumerates all 
of the foci in the 10,000 cells for each time point. A rep- 
resentative example of cells with increasing foci number 
is shown in Figure 1. 
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Figure 1. Figure 1 shows representative images of increas-
ing number of γ-H2AX foci in the lymphoblastoid cells cap- 
tured with imaging flow cytometry. The brightfield channel 
demonstrates the appearance of lymphoblastoid cells under 
light microscopy. The second channel represents the appea- 
rance of increasing numbers of γ-H2AX foci. The final co- 
lumn depicts the visualisation of the nuclear region of the 
cells by DRAQ5™ staining. Images of cells were captured 
at a magnification of 40×. 
 
2.9. Statistical Analysis 
Using the data analysis programme in Microsoft Excel, 
two-way analysis of variance was used to compare the 
distribution of foci in radiation-exposed cells in the pre- 
sence or absence of Olaparib, across the complete time 
course of the experiment. A Student’s unpaired t-Test 
was utilised to determine if there were differences in foci 
retention at specific time points following radiation ex- 
posure in the presence or absence of Olaparib. Data were 
regarded as significantly different in the P value was less 
than 0.05. 
3. Results 
3.1. Gamma H2AX Foci Analysis in Normal 
Lymphoblastoid Cells 
Gamma H2AX foci analysis was performed in two nor- 
mal lymphoblastoid cell lines (GM00893 and GM05423). 
Cells were exposed to 2 Gy gamma radiation in the pre- 
sence or absence of the PARP-1 inhibitor Olaparib and 
gamma H2AX foci were measured in un-irradiated cells 
and at 30 minutes, 3, 5 and 24 hours post-irradiation. The 
profiles of foci induction combined for GM00893 and 
GM05423 are shown in Figure 2. 
For normal cells with and without Olaparib exposure 
there is a predictable induction of foci at 30 minutes 
post-irradiation. In the cells not exposed to Olaparib 
there is a mean of 7.58 foci per cell, and in the Olaparib-  
 
Figure 2. Figure 2 shows the induction of γ-H2AX foci in the 
normal lymphoblastoid cells GM00893 and GM05423 plot- 
ted as an average graph. Data are derived from enumera- 
tion of foci in the images of approximately 10,000 cells cap- 
tured during imaging flow cytometry. Cells were treated 
with 2 Gy gamma radiation in the presence (black columns) 
or absence (white columns) of 5 m Olaparib. Foci were 
measured in untreated cells and those irradiated with 2 Gy 
gamma radiation at 0.5, 3, 5 and 24 hours post-irradiation. 
The data demonstrate a slight but significant retention of fo- 
ci in Olaparib-treated cells over a 24 hour period (ANOVA 
P > 0.05). However by comparing the 24 hours post-irra- 
diation time point alone, there was no significant difference 
in foci retention after irradiation with or without Olaparib 
(Student’s unpaired t-Test P < 0.05). 
 
treated cells this is slightly reduced at 6.83 foci per cell. 
Subsequently over a 24 hour period post-irradiation there 
is a decline in foci number in the normal cells, both Ola- 
parib-treated and untreated. At 24 hours this is reduced to 
near un-irradiated levels in the non-Olaparib-treated cells, 
at 2.38 foci per cell, and in the Olaparib-treated cells this 
figure is slightly higher at 3.24 foci per cell. 
Using analysis of variance to compare the time course 
distribution of post-2 Gy gamma radiation foci induction 
in the Olaparib-treated and untreated cells there is a sig- 
nificant difference in the distribution of foci (p = 0.012). 
However, using a Student’s t-Test to compare foci reten- 
tion at 24 hours in Olaparib-treated and untreated cells, 
there is no significant difference in foci numbers between 
treated and untreated cells (p = 0.315). This data indi- 
cates that Olaparib does not alter the repair of DNA DSB 
measured by gamma H2AX foci in lymphoblastoid cells 
derived from normal individuals. 
3.2. Gamma H2AX Foci Analysis in BRCA1 
Heterozygous Lymphoblastoid Cells 
Gamma H2AX foci analysis was performed following 2 
Gy gamma radiation in three lymphoblastoid cell lines 
(GM13705, GM14090 and GM16105) (details of expe- 
riment and analysis as above). The profiles of foci induc- 
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tion combined for GM13705, GM14090 and GM16105 
are shown in Figure 3. 
For BRCA1 heterozygous cells with and without Ola- 
parib exposure there is a predictable induction of foci at 
30 minutes post-irradiation. In the cells not exposed to 
Olaparib there is a mean of 5.23 foci per cell, and in the 
Olaparib-treated cells this is approximately the same at 
5.00 foci per cell. Subsequently over a 24 hour period 
post-irradiation there is a decline in foci number in the 
cells not treated with Olaparib; at 24 hours there is a 
mean of 2.00 foci per cell. However, in the Olaparib- 
treated cells there is retention of foci over the 24 hour 
period, so that the mean at 24 hours is 4.27 foci per cell, 
over twice the number of foci than in the untreated cells. 
Using analysis of variance to compare the time course 
distribution of post-2 Gy gamma radiation foci induction 
in the Olaparib-treated and untreated cells, there is a sig- 
nificant difference in the distribution of foci (p = 0.004). 
This significant difference is further verified with a Stu- 
dent’s t-Test. At 24 hours there is a significant retention 
of foci in the Olaparib-treated cells (p = 0.006). 
3.3. Gamma H2AX Foci Analysis in BRCA2  
Heterozygous Lymphoblastoid Cells 
Gamma H2AX foci analysis was performed following 2 
Gy gamma radiation in three lymphoblastoid cell lines 
(GM14170, GM14622 and GM14805) (details of expe- 
riment and analysis as above). The profiles of foci induc- 
tion combined for GM14170, GM14622 and GM14805 
are shown in Figure 4. 
For BRCA2 heterozygous cells with and without Ola- 
parib exposure there is a predictable induction of foci at 
30 minutes post-irradiation. In the cells not exposed to 
Olaparib there is a mean of 5.16 foci per cell, and in the 
Olaparib-treated cells this is approximately the same at 
5.90 foci per cell. Subsequently over a 24-hour period 
post-irradiation there is a decline in foci number in the 
BRCA2 heterozygous cells, both Olaparib-treated and 
untreated. At 24 hours this is reduced to slightly below 
un-irradiated levels in the non-Olaparib-treated cells, at 
1.29 foci per cell, and in the Olaparib-treated cells this 
figure is slightly higher at 2.02 foci per cell. 
Using analysis of variance to compare the time course 
distribution of post-2 Gy gamma radiation foci induction 
in the Olaparib-treated and untreated cells there is a sig- 
nificant difference in the distribution of foci (p = 0.004). 
However, using a Student’s t-Test to compare foci reten- 
tion at 24 hours in Olaparib-treated and untreated cells, 
there is no significant difference in foci numbers (p = 
0.181). This data indicates that Olaparib does not alter 
the repair of DNA DSB measured by gamma H2AX foci 
in lymphoblastoid cells derived from BRCA2 heterozy- 
gous individuals. 
 
Figure 3. Figure 3 shows the induction of γ-H2AX foci in 
three BRCA1 mono-allelic lymphoblastoid cell lines GM13705, 
GM14090 and GM16105 plotted as an average graph. Data 
are derived from enumerating the foci in the images of ap- 
proximately 10,000 cells captured during imaging flow cyto- 
metry. Cells were treated with 2 Gy gamma radiation in the 
presence (black columns) or absence (white columns) of 5 
m Olaparib. Foci were measured in untreated cells and 
those irradiated with 2 Gy gamma radiation at 0.5, 3, 5 and 
24 hours post-irradiation. The data demonstrate a slight but 
significant retention of foci in Olaparib treated cells over a 
24 hour period (ANOVA P > 0.05). However by comparing 
foci retention at 24 hours post-irradiation alone there is a 
significant retention of foci in the presence of Olaparib 
(Student’s t-Test P > 0.05). 
 
4. Discussion 
Radiotherapy is routinely employed in the clinical man- 
agement of cancer, frequently in conjunction with che- 
motherapy and/or surgery. The ionising radiation used in 
treatment creates single- and double-strand breaks in the 
DNA of both normal and tumour cells which if unrepair- 
ed can induce cell death. PARP inhibitors are chemothe- 
rapeutic agents prescribed to patients to accentuate the 
ionising radiation-induced DNA damage in tumour cells 
by inhibiting short-patch base-excision repair of DNA 
single-strand breaks. At replication forks where a SSB is 
encountered, the inhibition of PARP-1 by a drug such as 
Olaparib results in a DNA DSB [2], thus exacerbating ra- 
diation-induced DNA damage. These drugs are particular- 
ly effective in tumour cells homozygous for a mutation in 
the tumour suppressor genes BRCA1 and BRCA2 [16]. 
BRCA1 and BRCA2 proteins are involved in NHEJ and 
HR. BRCA1 is a versatile protein, participating in both 
the NHEJ and HR pathways, whereas BRCA2 is restrict- 
ed to HR. Hence cells where mutations in the BRCA 
genes have produced proteins with very little or no active 
function are likely to have reduced DSB repair capacity. 
NTT is the manifestation of damage to normal, non- 
cancerous tissue as a side-effect of anti-cancer therapy. 
There is no evidence to suggest that PARP inhibitors 
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Figure 4. Figure 4 shows the induction of γ-H2AX foci in 
three BRCA2 mono-allelic lymphoblastoid cell lines GM14170, 
GM14622 and GM14805 plotted as an average graph. Data 
are derived from enumerating the foci in the images of ap- 
proximately 10,000 cells captured during imaging flow cy- 
tometry. Cells were treated with 2 Gy gamma radiation in 
the presence (black columns) or absence (white columns) of 
5 m Olaparib. Foci were measured in untreated cells and 
those irradiated with 2 Gy gamma radiation at 0.5, 3, 5 and 
24 hours post-irradiation. The data demonstrate a slight but 
significant retention of foci in Olaparib treated cells over a 
24 hour period (ANOVA P > 0.05). However by comparing 
24 hours post-irradiation time point alone, there was no sig- 
nificant difference in foci retention after irradiation with or 
without Olaparib (Student’s unpaired t-Test P < 0.05). 
 
used as a single modality of treatment affect the survival 
of cells heterozygous for mutations in BRCA1 and BRCA2 
i.e. non-cancer cells [20]. However, PARP inhibitors us- 
ed in conjunction with other forms of cytotoxic therapy 
(such as radiotherapy) may cause significant toxicity in 
these heterozygous/non-cancer tissue cells [17]. This has 
important implications for the treatment of those cancer 
patients carrying a BRCA1 or BRCA2 mutation; in a pre- 
vious paper we cautioned that such patients may be sus- 
ceptible to elevated levels of NTT [17]. 
The previous study examined the response to ionising 
radiation of lymphoblastoid cells mono-allelic for either 
BRCA1 or BRCA2 mutations, when the cells had been 
exposed to the PARP inhibitor Olaparib. Cell survival 
was measured using the MTT assay. The combined cyto- 
toxic treatment did not affect cell survival in normal or 
BRCA2 heterozygote cells, but significantly enhanced 
cell death in the BRCA1 heterozygote cells. 
We hypothesised that he enhanced cellular radiation 
sensitivity of BRCA1 heterozygous cells exposed to Ola- 
parib was due to DSB retention. 
The number of foci per cell in each of the cell lines 
was measured over a time course of 24 hours post-irra- 
diation, and the results combined depending on cell type 
(normal, BRCA1-mutated and BRCA2-mutated). The 
number of foci per cell in all cell types, both treated with  
Olaparib and untreated, increased considerably 30 min- 
utes post-irradiation, then declined over the time course 
as the DSB were repaired and the γ-H2AX proteins were 
de-phosphorylated. We did observe a slight retention of 
foci in all cell types at the 24 hour time point in those 
cells treated with Olaparib. The exception to this trend 
was observed in the BRCA1-mutated cells treated with 
Olaparib. They retained almost the same number of foci 
per cell over the 24 hours, whereas over the same time 
period the number of foci per cell in untreated BRCA1- 
mutated cells decreased almost to pre-irradiated levels. 
This confirms our hypothesis that the enhanced cell death 
detected by the MTT assay in heterozygous BRCA1 cells 
was a result of unrepaired strand breaks in the DNA of 
these cells. 
The reasons as to why this enhanced cell death is ob- 
served in heterozygous BRCA1 cells treated with Ola- 
parib, when compared with untreated BRCA1 cells, is 
likely due to the specific functions of the PARP-1 in- 
hibitor Olaparib and the BRCA1 protein. The DNA single 
strand breaks created by exposure to ionising radiation 
are repaired by the BER pathway which requires the ac- 
tion of the PARP-1 enzyme. Inhibition of this enzyme by 
a drug such as Olaparib means SSB remain unrepaired. 
Furthermore, SSB are converted to DSB at replication 
fork sites, thus triggering the DNA DSB repair pathway 
(which includes the phosphorylation of the histone pro- 
tein H2AX to γ-H2AX), and the formation of γ-H2AX 
foci [21]. 
The BRCA1 protein has a variety of roles within DNA 
DSB repair, both in NHEJ and HR, and also interacts 
with tumour suppressor genes (e.g. p53) and other cell 
cycle regulators. The ubiquitous nature of the BRCA1 
protein in DNA repair means that a mutated/non-func- 
tioning protein may severely inhibit effective repair in 
both cycling and non-cycling cells. 
Another noticeable difference in the results arises from 
comparing the number of foci per cell detected in the 
normal cell lines with that reported in the BRCA-mutated 
cell lines. It can be seen from Figures 1-3 that normal 
cell lines report more foci per cell (and therefore more 
DNA DSB) at 30 minutes post-irradiation than either of 
the BRCA-mutated cell lines. There may be no single rea- 
son for this initially high level of reported DSB in normal 
cells, but a possible cause for this phenomenon includes 
the role of the BRCA1 protein in signal mediation imme- 
diately post-damage. Hence mutated BRCA1 proteins may 
inhibit the reporting of DNA damage in irradiated cells, 
although that does not explain the relatively low level of 
foci per cell in BRCA2-mutated cells 30 minutes post-ir- 
radiation. There may well be other, unidentified, reasons 
as to why this phenomenon occurs. 
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5. Conclusion 
In summary, this fundamental study of DSB repair kine- 
tics in a collection of lymphoblastoid cells mono-allelic 
for BRCA1 and BRCA2 indicates that the enhanced radia- 
tion sensitivity of BRCA1 heterozygous cells to radiation 
in the presence of Olaparib is caused by a persistence of 
DNA DSB. We reiterate that cancer patients with BRCA1 
mutations may experience unexpectedly severe NTT when 
treated with radiotherapy and PARP inhibitors. 
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Abbreviations 
ATM: Ataxia Telangiectasia Mutated Gene 
BER: Base Excision Repair 
BRCA1: Breast Cancer Susceptibility Gene 1 
BRCA2: Breast Cancer Susceptibility Gene 2 
DNA: Deoxyribose Nucleic Acid 
DRAQ 5: 1,5-Bis{[2-(di-methylamino) ethyl]amino}-4, 
8-dihydroxyanthracene-9, 10-dione 
DSB: Double Strand Break 
Gy: Gray 
HR: Homologous Recombination 
MRN: Mre11-Rad50-Nbs1 Complex 
NHEJ: Non Homologous End Joining 
NTT: Normal Tissue Toxicity 
PARP: Poly(ADP-ribose)polymerase 
PBS: Phosphate Buffered Saline 
 
 
 
